{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:24:28Z","timestamp":1783441468850,"version":"3.54.6"},"reference-count":30,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":772,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Craniopharyngiomas (CPs) are rare brain epithelial tumours arising in the suprasellar region, infiltrating adjacent areas causing visual loss, panhypopituitarism, cognitive deficits and morbid obesity. Papillary CPs (PCPs) harbour in 94% BRAF mutation cases. Two patients with PCP and BRAF V600E mutations but with different tumour status were treated with BRAF and MEK inhibitors. Case I was diagnosed with biopsy and treated for 16 months with BRAF and MEK inhibitors. After 3.5 months, there was a 50% reduction of the tumour volume, and after 13 months, the tumour volume decreased from 2220 to 90 mm3 (96%). Two months after stopping the drugs, he was treated with fractionated cranial irradiation (54 Gy). No recurrence of the PCP was recorded. Eight months after stopping the drugs, he was diagnosed with an adenocarcinoma of the oesophagus, which led to his death 12 months later. In case II, a woman had had four surgeries due to recurrences of a PCP, and a BRAF V600E mutation was confirmed. After a new recurrence measuring 14 \u00d7 12 \u00d7 18 mm, she was started on BRAF and MEK inhibitors. After 4 months of treatment, a significant decrease to 8 \u00d7 9 \u00d7 13 mm was recorded. The treatment continued for 31 months, and the MRI demonstrated a stable unchanged size including scar tissue, with a volume reduction from 633 to 483 mm3. During treatment, her visual acuity improved in her left eye from 0.05 to 0.3. After stopping the drugs, \u2018watchful waiting\u2019 with repeated MRI was decided. She is now off treatment for 25 months, without any recurrence on MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                    <jats:p>CPs are rare primary brain epithelial tumours arising in the suprasellar region from remnants of Rathke\u2019s pouch. CPs infiltrate adjacent areas causing visual loss, panhypopituitarism, cognitive deficits and morbid obesity. PCPs harbour in &amp;gt;90% BRAF V600E mutation. BRAF V600E mutation can successfully be treated with the combination of BRAF V600E and Mekinist inhibitors. It is suggested that PCP patients harbouring BRAF V600E mutation should be offered BRAF V600E and Mekinist inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-24-0024","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T13:42:56Z","timestamp":1730382176000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":2,"title":["Treatment with BRAF\/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma"],"prefix":"10.1530","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-9725","authenticated-orcid":true,"given":"Eva Marie","family":"Erfurth","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Sk\u00e5ne University Hospital 1 , ,","place":["Lund, Sweden"]},{"name":"Institution of Clinical Science, Lund University 2 , ,","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-690X","authenticated-orcid":true,"given":"Peter","family":"Siesj\u00f6","sequence":"additional","affiliation":[{"name":"Institution of Clinical Science, Lund University 2 , ,","place":["Lund, Sweden"]},{"name":"Department of Neurosurgery, Skane University Hospital 3 , ,","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-1236","authenticated-orcid":true,"given":"Pia C","family":"Sundgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences\/Diagnostic Radiology, Lund University, Lund University Bioimaging Centre 4 , ,","place":["Lund, Sweden"]},{"name":"Department of Medical Imaging and Physiology, Sk\u00e5ne University Hospital 5 , ,","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-0535","authenticated-orcid":true,"given":"Bj\u00f6rn","family":"Hammar","sequence":"additional","affiliation":[{"name":"Department of Ophtalmology, Clinical Sciences Lund, Lund University, Sk\u00e5ne University Hospital 6 , ,","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-5612","authenticated-orcid":true,"given":"Sara","family":"Kinhult","sequence":"additional","affiliation":[{"name":"Department of Oncology, Department of Clinical Sciences, Lund University, Sk\u00e5ne University Hospital 7 , ,","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2026070711073166900_bib1","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1200\/JCO.2013.50.4118","article-title":"BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1\/2 inhibition","volume":"31","author":"Andrews","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070711073166900_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026070711073166900_bib3","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070711073166900_bib4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary"},{"key":"2026070711073166900_bib5","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","article-title":"Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity","volume":"1","author":"Bernstein","year":"2020","journal-title":"J Neurosurg"},{"key":"2026070711073166900_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"key":"2026070711073166900_bib8","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026070711073166900_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070711073166900_bib9","first-page":"3897","article-title":"Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumour recurrence","volume":"11","author":"Bulow","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711073166900_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","article-title":"The descriptive epidemiology of craniopharyngioma","volume":"89","author":"Bunin","year":"1998","journal-title":"J Neurosurg"},{"key":"2026070711073166900_bib11","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070711073166900_bib12","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070711073166900_bib13","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1200\/JCO.2013.51.5783","article-title":"New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma","volume":"33","author":"Carlino","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026070711073166900_bib14","doi-asserted-by":"crossref","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","article-title":"Aggressive childhood-onset papillary craniopharyngioma managed with vemurafenib, a BRAF inhibitor","volume":"5","author":"Chik","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026070711073166900_bib15","first-page":"vdaa141","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Di Stefano","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026070711073166900_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1159\/000509616","article-title":"Diagnosis, background and treatment of hypothalamic damage in craniopharyngioma","volume":"110","author":"Erfurth","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026070711073166900_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070711073166900_bib18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070711073166900_bib20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report","volume":"130","author":"Himes","year":"2019","journal-title":"J Neurosurg"},{"key":"2026070711073166900_bib21","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"key":"2026070711073166900_bib22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070711073166900_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0065-230X(08)60765-4","article-title":"Signal transduction through MAP kinase cascades","volume":"74","author":"Lewis","year":"1998","journal-title":"Adv Cancer Res"},{"key":"2026070711073166900_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"7","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"2026070711073166900_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026070711073166900_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jc.2014-3525","article-title":"Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population- based study in Sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711073166900_bib27","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"key":"2026070711073166900_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol"},{"key":"2026070711073166900_bib29","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir"},{"key":"2026070711073166900_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","article-title":"Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes","volume":"17","author":"Sterkenburg","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026070711073166900_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/4\/1\/EO-24-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/4\/1\/EO-24-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0024\/10876\/eo-24-0024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0024\/10876\/eo-24-0024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:43:34Z","timestamp":1783439014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/4\/1\/e240024\/1577\/Treatment-with-BRAF-MEK-inhibitors-in-mutant-BRAF"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-24-0024","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"e240024"}}